Mike Kratky
Stock Analyst at Leerink Partners
(3.53)
# 912
Out of 4,711 analysts
26
Total ratings
50%
Success rate
38.06%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $80.04 | +8.70% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $187.77 | +4.92% | 2 | Sep 10, 2024 | |
| TXG 10x Genomics | Initiates: Outperform | $35 | $14.04 | +149.29% | 1 | Sep 3, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $242.54 | +8.44% | 1 | Sep 3, 2024 | |
| NARI Inari Medical | Initiates: Market Perform | $47 | $55.45 | -15.24% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $35.91 | +25.31% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $11.53 | +90.81% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $266.57 | -30.97% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $56.50 | -25.66% | 1 | Oct 16, 2023 | |
| ISRG Intuitive Surgical | Initiates: Outperform | $342 | $524.43 | -34.79% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $74.81 | +0.25% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $81.17 | -54.42% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $15.64 | -42.46% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $4.70 | +963.83% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $13.21 | +240.65% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $308.44 | +2.13% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $40.66 | -23.76% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $25.86 | -45.86% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $19.03 | +110.19% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $48 | $0.83 | +5,715.36% | 1 | Aug 11, 2022 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $80.04
Upside: +8.70%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $187.77
Upside: +4.92%
10x Genomics
Sep 3, 2024
Initiates: Outperform
Price Target: $35
Current: $14.04
Upside: +149.29%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $242.54
Upside: +8.44%
Inari Medical
Sep 3, 2024
Initiates: Market Perform
Price Target: $47
Current: $55.45
Upside: -15.24%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $35.91
Upside: +25.31%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $11.53
Upside: +90.81%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $266.57
Upside: -30.97%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $56.50
Upside: -25.66%
Intuitive Surgical
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $524.43
Upside: -34.79%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $74.81
Upside: +0.25%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $81.17
Upside: -54.42%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $15.64
Upside: -42.46%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $4.70
Upside: +963.83%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $13.21
Upside: +240.65%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $308.44
Upside: +2.13%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $40.66
Upside: -23.76%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $25.86
Upside: -45.86%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $19.03
Upside: +110.19%
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $0.83
Upside: +5,715.36%